✦ LIBER ✦

Excess burden of constipation in Parkinson's disease: A pilot study

✍ Scribed by Julie Kaye; Heather Gage; Alan Kimber; Lesley Storey; Patrick Trend

Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 61 KB
Volume: 21
Category: Article
ISSN: 0885-3185
DOI: 10.1002/mds.20942

No coin nor oath required. For personal study only.

✦ Synopsis

An analysis was undertaken of clinic-based questionnaires that asked people with Parkinson's disease and a control group of older people without a known neurological condition about their experiences of constipation. People with Parkinson's disease report higher constipation on a validated objective measure, the Rome criterion (59% vs. 20.9%); a behavioral indicator, laxative-taking (38.4% vs. 14.2%); and subjective self-report of being always or often concerned by it (33.4% vs. 6.1%). Many people with Parkinson's disease experience constipation problems but they may not bring these to the attention of their healthcare providers. More research is required to understand the causes and management options.

📜 SIMILAR VOLUMES

Burden of illness in Parkinson's disease

✍ Daniel M. Huse; Kathy Schulman; Lucinda Orsini; Jane Castelli-Haley; Sean Kenned 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 85 KB

## Abstract This study quantifies direct medical care costs for individual patients with Parkinson's disease (PD) and projects total national costs of PD. Anonymous, patient‐level data on health care utilization and cost were obtained from Medstat's MarketScan Research Databases. Patients were sele

Bright light therapy in Parkinson's dise

Bright light therapy in Parkinson's disease: A pilot study

✍ Sebastian Paus; Tanja Schmitz-Hübsch; Ullrich Wüllner; Antje Vogel; Thomas Klock 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 62 KB 👁 2 views

## Abstract Several observations suggest a beneficial effect of melatonin antagonism for Parkinson's disease (PD). Although bright light therapy (BLT) suppresses melatonin release and is an established treatment for depression and sleep disturbances, it has not been evaluated in PD. We examined eff

Ethosuximide and tremor in Parkinson's d

Ethosuximide and tremor in Parkinson's disease: A pilot study

✍ E. Pourcher; B. Gomez-Mancilla; Dr. P. J. Bédard 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 376 KB 👁 1 views

## Abstract Following the demonstration of an antitremor effect of ethosuximide in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) monkey model, we have tested the effect of this drug in 10 patients with typical parkinsonian tremor. Six patients suffered from Parkinson's disease with promin

Does fluoxetine aggravate Parkinson's di

Does fluoxetine aggravate Parkinson's disease? A pilot prospective study

✍ Jean-Louis Montastruc; Nelly Fabre; Olivier Blin; Jean-Michel Senard; Olivier Ra 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 366 KB 👁 1 views

Macrogol for the treatment of constipati

Macrogol for the treatment of constipation in Parkinson's disease. A randomized placebo-controlled study

✍ Roberta Zangaglia; Emilia Martignoni; Margaret Glorioso; Maria Ossola; Giulio Ri 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 87 KB 👁 2 views

## Abstract Chronic constipation is the most frequent symptom of autonomic system involvement in Parkinson's disease (PD). Quite often the symptom is severe and impairs patients' quality of life. The objective of this study is to determine the efficacy and safety of an isosmotic macrogol solution f

Caffeine in Parkinson's disease: A pilot

Caffeine in Parkinson's disease: A pilot open-label, dose-escalation study

✍ Robert D. Altman; Anthony E. Lang; Ronald B. Postuma 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 314 KB 👁 1 views

## Abstract ## Introduction: Epidemiologic studies consistently find an inverse association between caffeine use and PD. Numerous explanations exist, but are difficult to evaluate as caffeine's symptomatic effect and tolerability in PD are unknown. ## Patients and Methods: We designed an open‐la